###### Strengths and limitations of this study

-   The relationship between body mass index and mortality was evaluated by controlling the variables related to various diseases, which could not be obtained in previous studies.

-   We addressed the existence of multi-morbidity by Charlson comorbidity index.

-   This is a hospital-based study involving a single tertiary hospital whose data could not be generalised.

Introduction {#s1}
============

Obesity is one of the established risk factors for stroke, in which prevention guidelines recommend weight reduction.[@R1] However, in patients who have experienced a stroke, an inverse relationship was reported between obesity and unfavourable clinical outcomes, such as readmission, stroke recurrence and mortality, in contrast to that of the general population.[@R2] This paradox was also observed in other chronic diseases such as heart failure, diabetes, chronic kidney disease, and peripheral vascular disease.[@R9]

The obesity paradox remains to be fully explained and even criticised as an artificial finding associated with selection bias, that is, a confounding result due to uncontrolled risk factors commonly correlated with mortality and obesity.[@R13] One obvious confounder is comorbidities. Some comorbidities such as infections or malignant diseases can cause unintended weight loss and death.[@R16] Other significant confounders are age and stroke severity. In several studies on the obesity paradox, patients with lower body mass index (BMI) were older and had higher stroke severity, consequently causing an increased mortality risk.[@R17] Previous studies on Korean patients with ischaemic stroke[@R18] also showed that the initial relationship between obesity and short-term clinical outcome[@R19] or long-term mortality[@R18] cease to exist after adjusting for stroke severity.

Comorbidities, age and stroke severity are the most critical outcome determinants after an ischaemic stroke incident. Hence, in this paper, we examine the relationship between obesity-related mortality and all-cause mortality among patients with ischaemic stroke after adjusting the effect of stroke severity (based on the National Institutes of Health Stroke Scale (NIHSS) score) and other severe comorbidities from a detailed registry data in a clinical setting. The NIHSS score is an excellent indicator of stroke severity. We also determine whether the relationship is consistent regardless of patients' age.

Materials and methods {#s2}
=====================

Data source and study subjects {#s2-1}
------------------------------

The study subjects were from the Yonsei Stroke Registry, a hospital-based stroke registry established in 1994.[@R20] We identified all patients aged 20 years and above who were admitted for acute ischaemic stroke from January 2007 to June 2013. The Yonsei Stroke Registry admits only patients with acute ischaemic stroke who were seen by a neurologist within 7 days of clinical onset. All of the patients have acute cerebral infarctions and have been presented to the neurologists within 7 days of onset. The diagnosis of cerebral infarction was based on clinical features related to neuroimaging studies such as CT or MRI, which was confirmed by the agreement of two or more staff neurologists. We excluded patients younger than 20 years and those without height or weight data. Registered patients were routinely followed up in the outpatient clinic until their death. Moreover, the deaths were confirmed by matching the death records and the cause of death obtained from the Korean National Statistical Office. The causes of death were classified according to the International Classification of Disease, 10th revision. Furthermore, stroke-related mortality included the fatal stroke (I60--64),[@R21] whereas cardiovascular-event-related mortality included I00--I99.

Variables {#s2-2}
---------

### Obesity {#s2-2-1}

Height and weight were measured at the time of registration. BMI was calculated as the ratio of weight (kg) and the square of height (m^2^). Then, the patients were classified into four groups based on their BMI at the time of stroke. Obese I and obese II categories were combined to a single obese category, and BMI levels were classified according to the guidelines for the Asian-Pacific population[@R22]: underweight (BMI \<18.5 kg/m^2^), normal weight (18.5≤BMI \< 23 kg/m^2^), overweight (23≤BMI \< 25 kg/m^2^) and obese (BMI ≥25 kg/m^2^). The normal weight group was used as the reference group.

### Clinical outcomes {#s2-2-2}

The primary outcomes were all-cause mortality in the short term (within 3 months), intermediate term (within 1 year) and long term (longer than 1 year) after the stroke incident. Meanwhile, the secondary outcomes were stroke-related mortality and cardiovascular-event-related mortality, and the occurrence of those outcomes was ascertained based on the discharge records or death records.

### Covariates {#s2-2-3}

The initial stroke severity was evaluated using the NIHSS score, which ranges from 0 to 42 based on the 15 elements of neurological examinations in various aspects of individual physical functions.[@R23] To identify potential confounders of the relationship between BMI and mortality, we reviewed the literature and obtained the following covariates from the registry: age,[@R24] gender,[@R25] current smoking status,[@R1] any complication that occurred during admission[@R29] and comorbidities---including previous stroke,[@R29] diabetes,[@R29] hypercholesterolaemia,[@R31] depression,[@R32] dementia,[@R33] anaemia,[@R34] atrial fibrillation[@R35] and active cancer. In addition to the NIHSS score, we included the Charlson comorbidity index (CCI) and cardiovascular risk parameters at admission, such as blood glucose level, systolic blood pressure and total cholesterol level at the time of the index stroke diagnosis.

Active cancer was defined as any cancer diagnosed within 6 months before the stroke: recently recurrent cancer, progressive cancer, or any malignancy requiring curative or palliative treatment within the previous 6 months.[@R36] Complications included brain herniation, intracerebral haemorrhage, any infection (such as pneumonia, urinary tract infection and sepsis) and any bleeding other than intracerebral haemorrhage. The CCI is a widely used weighted composite index for comorbidities, such as myocardial infarction, congestive heart failure, peripheral vascular disease or bypass, previous cerebrovascular accident or transient ischaemic attack, dementia, chronic pulmonary disease, gastrointestinal ulcer disease, liver disease, moderate or severe renal disease, connective tissue disease or rheumatic disease, diabetes, diabetes with end-organ damage, AIDS, non-metastatic solid tumour, leukaemia, lymphoma, multiple myeloma, and metastatic tumour.[@R37] Note that we did not include the age factor when calculating CCI.

Patients with hypertension were managed to maintain normal blood pressure. Shock is also a critical life-threatening emergency in patients with stroke. Therefore, we considered both hypertension and hypotension as risk factors for mortality. Since blood pressure fluctuates and only one measurement was obtained under a stressful condition, we defined the lower risk range of systolic blood pressure as 90 to 180 mm Hg.[@R38] It is known that both hypoglycaemia and hyperglycaemia can increase the risk of death. Since diabetes was included in the covariate and considering recommendations on glycaemic control and meta-analysis result,[@R30] we defined the reference level of blood glucose as 3.9--10 mmol/L (70--180 mg/dL). Considering that stroke treatment may last over 7 years, all models were adjusted based on the enrolment year. Using 2007 as the reference group, we created dummy variables representing the year of initial stroke hospitalisation.

Subgroup analyses were conducted based on age (less than 65 and 65 years and above) for all-cause mortality.

Statistical analysis {#s2-3}
--------------------

The characteristics of the study groups were analysed using analysis of variance tests, and Kruskal-Wallis test and χ^2^ tests were used for continuous variables and categorical variables, respectively. Kaplan-Meier analysis was used to determine the relationship between categorical BMI and all-cause or stroke-related mortality. We used multivariate Cox proportional hazard models to analyse the relationship between BMI and mortality within 3 months, 1 year and over 1 year. The multivariate models were adjusted for age, gender and smoking status. The same analysis was conducted by additionally adjusting for comorbidities, CCI, shock or extremely high blood pressure, hypoglycaemia or hyperglycaemia at admission, total cholesterol level at admission, NIHSS score, any complications, enrolment year, treatment modalities (any thrombolysis, tissue plasminogen activator use, intra-arterial thrombolysis, mechanical thrombectomy and stent insertion), and statin use. Progression from stroke-related mortality was assessed using the Fine-Grey competing risk model, treating other-cause mortality as a competing risk. We also performed competing risk analysis with cardiovascular-event-related death as the primary event of interest and non-cardiovascular mortality as a competing event. Stratified analyses based on the patient's age group were performed. However, because dementia and hypoglycaemia were rare in younger patients, we excluded these variables for ages less than 65 years in the subgroup analysis. Furthermore, statistical analyses were performed using Stata V.14 (College Town, TX, USA).

Patient and public involvement {#s2-4}
------------------------------

Patients and the public were not involved in this analysis.

Results {#s3}
=======

Sample characteristics {#s3-1}
----------------------

A total of 3599 patients with ischaemic stroke aged 20 years and older were identified from the registry from January 2007 to June 2013. In all, 15 patients (0.4%) were excluded because of missing height or weight data, and thus, only 3584 patients remained as the final sample. Compared with patients with accurate height and weight information, those without such data were older, had a severe stroke and showed higher short-term mortality.

[Table 1](#T1){ref-type="table"} summarises the baseline characteristics of the final sample. The mean age of the studied patients was 66 (range, 20--104) years. The mean BMI was 23.7 kg/m^2^; 164 (4.6%) patients were underweight, 1321 (36.9%) were normal weight, 943 (26.3%) were overweight and 1156 (32.2%) were obese. Patients were followed up for a mean period of 1133 days after the index event. A total of 824 patients (23%) died, and the mean duration until death was 545 days, where 284 patients (7.9%) died of a stroke, with a mean duration until stroke-related death of 360 days. In the subgroup of patients aged less than 65 years, 159 (11.1%) died during the follow-up period, whereas the mortality of elderly patients aged 65 years and above was 31% (665 patients).

###### 

Summary statistics

  Variables (n=3584)                                                   Mean±SD, N (%), median (IQR)
  -------------------------------------------------------------------- ------------------------------
  Key independent variables                                            
   BMI (kg/m^2^)                                                       23.7±3.3(11.4--40.1)
   Underweight (BMI \<18.5)                                            164 (4.6)
   Normal (18.5≤BMI \< 23)                                             1321 (36.9)
   Overweight (23≤BMI \< 25)                                           943 (26.3)
   Obese (BMI ≥25)                                                     1156 (32.2)
  Outcomes                                                             
   All-cause mortality                                                 
    Within 3 months                                                    248 (6.9)
    Within 1 year                                                      425 (11.9)
    After 1 year                                                       824 (23.0)
   Stroke-related mortality                                            
    Within 3 months                                                    130 (3.6)
    Within 1 year                                                      187 (5.2)
    After 1 year                                                       284 (7.9)
  Covariates                                                           
   NIHSS on admission                                                  3(1--7)
   Age                                                                 66±12.4
    20--64 years                                                       1439 (40.2)
    ≥65 years                                                          2145 (59.8)
   Sex                                                                 
    Male\*                                                             2175 (60.7)
  Comorbidities                                                        
   Atrial fibrillation\*                                               803 (22.4)
   Depression\*                                                        197 (5.5)
   Dementia\*                                                          107 (3.0)
   Previous stroke or transient ischaemic attack\*                     470 (13.1)
   Anaemia\*                                                           616 (17.2)
   Active cancer\*                                                     205 (5.7)
   Liver disease\*                                                     109 (3.0)
   Moderate or severe renal disease\*                                  300 (8.4)
   Diabetes\*                                                          1138 (31.8)
   Hypercholesterolaemia\*                                             747 (20.8)
   Charlson comorbidity index                                          1 \[0--2)
   Current smoking\*                                                   854 (23.8)
  Initial systolic blood pressure (mm Hg)                              
   90≤SBP \< 180                                                       2913 (81.3)
   Shock (SBP \<90)\*                                                  12 (0.3)
   Extremely high blood pressure (SBP ≥180)\*                          659 (18.4)
  Initial blood glucose (mmol/L)                                       
   3.9≤glucose \< 10                                                   2935 (81.9)
   Hypoglycaemia (glucose \<3.9)\*                                     15 (0.42)
   Poorly controlled hyperglycaemia (glucose ≥10)\*                    634 (17.7)
   Initial total cholesterol (mg/dL)                                   181±43
  Subtypes of ischaemic stroke                                         
   Large artery atherosclerosis                                        741 (20.7)
   Cardioembolism                                                      980 (27.3)
   Small vessel occlusion                                              319 (8.9)
   Stroke of other determined aetiology                                86 (2.4)
   Stroke of undetermined aetiology because of incomplete evaluation   10 (0.3)
   Stroke of undetermined aetiology because of negative evaluation     781 (21.8)
   Stroke of undetermined aetiology because of two or more causes      667 (18.6)
   Any complications\*                                                 588 (16.4)
  Treatment\*                                                          
   Any thrombolysis                                                    407 (11.4)
   Tissue plasminogen activator                                        275 (7.7)
   Intra-arterial thrombolysis                                         163 (4.6)
   Mechanical thrombectomy                                             126 (3.5)
   Stent insertion                                                     111 (3.1)
   Antiplatelet                                                        1146 (32.0)
   Anticoagulation                                                     206 (5.8)
   Statin                                                              610 (17)
  Fiscal year of stroke onset                                          
   2007                                                                522 (14.6)
   2008                                                                541 (15.1)
   2009                                                                642 (17.9)
   2010                                                                512 (14.3)
   2011                                                                561 (15.6)
   2012                                                                523 (14.6)
   2013                                                                283 (7.9)

\*Dummy variables.

BMI, body mass index; NIHSS, National Institute of Health Stroke Scale; SBP, systolic blood pressure.

[Table 2](#T2){ref-type="table"} shows the baseline characteristics among obesity subgroups. Underweight patients were older and more likely to have higher NIHSS scores, atrial fibrillation, anaemia, active cancer, shock and complications. Obese patients were younger and more likely to have diabetes, hypercholesterolaemia and higher initial total cholesterol.

###### 

Univariate analysis of covariates between obesity groups

  ----------------------------------------------------------------------------------------------------------------------------------------
  Covariates                                                          Underweight\   Normal weight\   Overweight\   Obese\       P value
                                                                      (n=164)        (n=1321)         (n=943)       (n=1156)     
  ------------------------------------------------------------------- -------------- ---------------- ------------- ------------ ---------
  NIHSS on admission                                                  5 (2--14)      4 (2--8)         3 (1--7)      3 (1--6)     \<0.001

  Age                                                                 71.7±14.3      67.6±12.4        66.0±11.6     63.3±12.2    \<0.001

  Sex, male                                                           80 (48.8)      773 (58.5)       640 (67.9)    682 (59)     \<0.001

  Atrial fibrillation                                                 55 (33.5)      316 (23.9)       211 (22.4)    221 (19.1)   \<0.001

  Depression                                                          17 (10.4)      83 (6.3)         47 (5.0)      50 (4.3)     0.006

  Dementia                                                            8 (4.9)        42 (3.2)         34 (3.6)      23 (2.0)     0.06

  Previous stroke or transient ischaemic attack                       27 (16.5)      161 (12.2)       119 (12.6)    163 (14.1)   0.284

  Anaemia                                                             63 (38.4)      283 (21.4)       128 (13.6)    142 (12.3)   \<0.001

  Active cancer                                                       13 (7.9)       91 (6.9)         52 (5.5)      49 (4.2)     0.022

  Liver disease                                                       5 (3.1)        30 (2.3)         29 (3.1)      45 (3.9)     0.138

  Moderate or severe renal disease                                    21 (12.8)      130 (9.8)        66 (7.0)      83 (7.2)     0.006

  Diabetes                                                            37 (22.6)      389 (29.5)       290 (30.8)    422 (36.5)   \<0.001

  Hypercholesterolaemia                                               23 (14.0)      245 (18.6)       189 (20.0)    290 (25.1)   \<0.001

  Charlson comorbidity index                                          1 \[0--2.5)    1 \[0--2)        1 \[0--2)     1 \[0--2)    0.016

  Current smoking                                                     27 (16.5)      309 (23.4)       244 (25.9)    274 (23.7)   0.065

  Shock (SBP \<90)                                                    3 (1.8)        6 (0.5)          2 (0.2)       1 (0.1)      0.003

  Extremely high blood pressure (SBP ≥180)                            33 (20.1)      234 (17.8)       168 (17.8)    224 (19.4)   0.640

  Initial hypoglycaemia (glucose \<3.9)                               0 (0)          7 (0.5)          5 (0.5)       3 (0.3)      0.559

  Poorly controlled hyperglycaemia (glucose ≥10)                      23 (14.0)      219 (16.6)       165 (17.5)    227 (19.6)   0.129

  Initial total cholesterol (mmol/L)                                  171±40         179±42           180±42        186±45       \<0.001

  Large artery atherosclerosis                                        28 (17.1)      255 (19.3)       180 (19.1)    278 (24.1)   0.006

  Cardioembolism                                                      58 (35.4)      372 (28.2)       264 (28.0)    286 (24.7)   0.019

  Small vessel occlusion                                              14 (8.5)       112 (8.5)        90 (9.5)      103 (8.9)    0.850

  Stroke of other determined aetiology                                4 (2.4)        32 (2.4)         21 (2.2)      29 (2.5)     0.980

  Stroke of undetermined aetiology because of incomplete evaluation   1 (0.6)        2 (0.2)          3 (0.3)       4 (0.4)      0.647

  Stroke of undetermined aetiology because of negative evaluation     29 (17.7)      279 (21.1)       212 (22.5)    261 (22.6)   0.448

  Stroke of undetermined aetiology because of two or more causes      30 (18.3)      269 (20.4)       173 (18.4)    195 (16.9)   0.168

  Any complications                                                   50 (30.5)      239 (18.1)       133 (14.1)    166 (14.4)   \<0.001

  Any thrombolysis                                                    26 (15.9)      158 (12.0)       106 (11.2)    117 (10.1)   0.136

  Tissue plasminogen activator                                        19 (11.6)      107 (8.1)        62 (6.6)      87 (7.5)     0.137

  Intra-arterial thrombolysis                                         12 (7.3)       71 (5.4)         43 (4.6)      37 (3.2)     0.020

  Mechanical thrombectomy                                             4 (2.4)        49 (3.7)         41 (4.4)      32 (2.8)     0.209

  Stent insertion                                                     5 (3.1)        40 (3.0)         42 (4.5)      24 (2.1)     0.020

  Antiplatelet                                                        58 (35.4)      410 (31.0)       315 (33.4)    363 (31.4)   0.482

  Anticoagulation                                                     9 (5.5)        79 (6.0)         54 (5.7)      64 (5.5)     0.969

  Statin                                                              31 (18.9)      192 (14.5)       186 (19.7)    201 (17.4)   0.011
  ----------------------------------------------------------------------------------------------------------------------------------------

NIHSS, National Institute of Health Stroke Scale; SBP, systolic blood pressure.

Stroke-related mortality and cardiovascular-event-related mortality in the total population {#s3-2}
-------------------------------------------------------------------------------------------

Stroke-related mortality was highest in the underweight patients and lowest in the obese patients (see [figure 1A](#F1){ref-type="fig"}). After adjustment of age, gender and smoking status, the overweight had a lower probability of long-term mortality---subdistribution HR (SHR)=0.73, 95% CI: 0.54 to 0.99---(see [table 3](#T3){ref-type="table"}, Model 1). However, after further adjustment of comorbidities, the obesity paradox disappeared (see [table 3](#T3){ref-type="table"}, Model 2). For cardiovascular-event-related mortality, the overweight and obese groups had a lower probability of long-term mortality (SHR=0.72, 95% CI: 0.55 to 0.95 for the overweight group; SHR=0.67, 95% CI: 0.51 to 0.89 for the obese group) in Model 1. After further adjustment, the obese group still had a lower probability of long-term mortality (SHR=0.66, 95% CI: 0.49 to 0.90; see [table 3](#T3){ref-type="table"}, Model 2).

###### 

Adjusted HRs of the obesity status on stroke-related mortalities and cardiovascular-event-related mortality

  Variables                                3 months   1 year         After 1 year                         
  ---------------------------------------- ---------- -------------- -------------- -------------- ------ --------------
  Stroke-related mortality                                                                                
   Model 1\*                                                                                              
    Underweight                            1.63       0.91 to 2.91   1.52           0.93 to 2.48   1.39   0.91 to 2.12
    Normal weight                          1.00                      1.00                          1.00   
    Overweight                             0.68       0.42 to 1.11   0.70           0.47 to 1.03   0.73   0.54 to 0.99
    Obese                                  1.01       0.65 to 1.57   0.81           0.56 to 1.18   0.76   0.56 to 1.03
   Model 2†                                                                                               
    Underweight                            1.12       0.61 to 2.05   1.56           0.93 to 2.61   1.42   0.91 to 2.23
    Normal weight                          1.00                      1.00                          1.00   
    Overweight                             0.85       0.55 to 1.34   0.84           0.55 to 1.26   0.83   0.61 to 1.15
    Obese                                  0.87       0.56 to 1.34   0.92           0.61 to 1.38   0.82   0.58 to 1.14
  Cardiovascular-event-related mortality                                                                  
   Model 1\*                                                                                              
    Underweight                            1.23       0.70 to 2.16   1.15           0.71 to 1.86   1.08   0.72 to 1.62
    Normal weight                          1.00                      1.00                          1.00   
    Overweight                             0.69       0.45 to 1.05   0.71           0.51 to 0.99   0.72   0.55 to 0.95
    Obese                                  0.83       0.55 to 1.25   0.70           0.49 to 0.99   0.67   0.51 to 0.89
   Model 2†                                                                                               
    Underweight                            1.12       0.62 to 2.05   1.05           0.63 to 1.77   0.98   0.63 to 1.53
    Normal weight                          1.00                      1.00                          1.00   
    Overweight                             0.85       0.54 to 1.33   0.86           0.60 to 1.23   0.83   0.63 to 1.11
    Obese                                  0.87       0.56 to 1.35   0.73           0.50 to 1.07   0.66   0.49 to 0.90

\*Model 1 was adjusted for age, gender and smoking status.

†Model 2 adjusted the following covariates in addition to what were controlled in Model 1: comorbidities (diabetes, old stroke, atrial fibrillation, active cancer, anaemia, renal disease, liver disease, hypercholesterolaemia, depression, dementia, any complications, initial systolic blood pressure status, total cholesterol, initial glucose level and Charlson comorbidity index), enrolment year, stroke severity measured using the NIHSS score, treatment modalities (any thrombolysis, tissue plasminogen activator, intra-arterial thrombolysis, mechanical thrombectomy and stent insertion) and statin use.

NIHSS, National Institute of Health Stroke Scale; SHR, subdistribution hazard ratio.

![Survival curves for (A) stroke-related mortality and (B) all-cause mortality in patients with ischaemic stroke according to their body mass index.](bmjopen-2018-028880f01){#F1}

All-cause mortality in the total population {#s3-3}
-------------------------------------------

In the unadjusted analysis, all-cause mortality increased with lower BMI (see [figure 1B](#F1){ref-type="fig"}). The all-cause mortality risks in covariate-adjusted analysis remained higher in the underweight group than in the normal weight group for all investigated durations (HR=1.55, 95% CI: 1.00 to 2.42 for 3-month mortality; HR=1.54, 95% CI: 1.09 to 2.18 for 1-year mortality; HR=1.43, 95% CI: 1.09 to 1.87 for long-term mortality). By contrast, after adjusting for the confounding variables, the obese group had a lower risk than the normal weight group by 19% for 3-month mortality (HR=0.81, 95% CI: 0.56 to 1.16), 27% for 1-year mortality (HR=0.73, 95% CI: 0.55 to 0.99) and 34% for mortality of 1 year and above (HR=0.66, 95% CI: 0.54 to 0.82; see [table 4](#T4){ref-type="table"}).

###### 

All-cause mortality stratified by age group

  Variables         3 months   1 year         After 1 year                         
  ----------------- ---------- -------------- -------------- -------------- ------ --------------
  Model 1\*                                                                        
   Total cohort                                                                    
    Underweight     1.96       1.31 to 2.93   1.89           1.37 to 2.59   1.61   1.25 to 2.09
    Normal weight   1.00                                                           
    Overweight      0.60       0.42 to 0.85   0.70           0.54 to 0.90   0.83   0.70 to 0.98
    Obese           0.67       0.48 to 0.94   0.63           0.48 to 0.82   0.63   0.53 to 0.82
   Age \<65 years                                                                  
    Underweight     3.75       1.66 to 8.47   3.49           1.36 to 7.22   2.54   1.32 to 4.89
    Normal weight   1.00                      1.00                          1.00   
    Overweight      0.81       0.41 to 1.56   0.83           0.48 to 1.46   0.91   0.61 to 1.34
    Obese           0.28       0.12 to 0.63   0.53           0.30 to 0.91   0.58   0.39 to 0.86
   Age≥65 years                                                                    
    Underweight     1.57       1.00 to 2.47   1.59           1.12 to 2.25   1.46   1.10 to 1.93
    Normal weight   1.00                      1.00                          1.00   
    Overweight      0.54       0.36 to 0.81   0.67           0.51 to 0.89   0.82   0.68 to 0.99
    Obese           0.89       0.62 to 1.27   0.70           0.52 to 0.93   0.6    0.54 to 0.82
  Model 2†                                                                         
   Total cohort                                                                    
    Underweight     1.55       1.00-2.47      1.54           1.09-2.18      1.43   1.09-1.87
    Normal weight   1.00                      1.00                          1.00   
    Overweight      0.78       0.54-1.13      0.89           0.69-1.14      0.98   0.82-1.16
    Obese           0.81       0.56-1.16      0.73           0.55-0.99      0.66   0.54-0.82
   Age \<65 years                                                                  
    Underweight     0.64       0.15 to 2.82   0.73           0.22 to 2.44   0.98   0.41 to 2.35
    Normal weight   1.00                      1.00                          1.00   
    Overweight      1.27       0.59 to 2.74   1.36           0.73 to 2.54   1.43   0.92 to 2.21
    Obese           0.43       0.17 to 1.12   0.72           0.40 to 1.31   0.77   0.49 to 1.21
   Age≥65 years                                                                    
    Underweight     1.49       0.92 to 2.41   1.50           1.03 to 2.19   1.42   1.06 to 1.92
    Normal weight   1.00                      1.00                          1.00   
    Overweight      0.59       0.39 to 0.91   0.77           0.58 to 1.02   0.91   0.75 to 1.10
    Obese           0.96       0.65 to 1.44   0.73           0.52 to 1.03   0.65   0.52 to 0.83

\*Model 1 was adjusted for age, gender and smoking status.

†Model 2 adjusted the following covariates in addition to what were controlled in Model 1: comorbidities (diabetes, old stroke, atrial fibrillation, active cancer, anaemia, renal disease, liver disease, hypercholesterolaemia, depression, dementia, any complications, initial systolic blood pressure status, total cholesterol, initial glucose level and Charlson comorbidity index), enrolment year, stroke severity measured using the NIHSS score, treatment modalities (any thrombolysis, tissue plasminogen activator, intra-arterial thrombolysis, mechanical thrombectomy and stent insertion) and statin use.

NIHSS, National Institute of Health Stroke Scale.

All-cause mortality stratified by age group {#s3-4}
-------------------------------------------

The all-cause mortality was lower in the higher BMI groups in both elderly (of age 65 years and above) and younger (of age less than 65 years) subgroups (see [figure 2A and B](#F2){ref-type="fig"}) in the unadjusted analyses. The obesity paradox was still observed even after adjustment for age, gender and smoking status and was more evident in the younger group in all investigated durations (see [table 4](#T4){ref-type="table"}, Model 1). However, after further adjustment for comorbidities, such associations disappeared in the younger group. By contrast, in the older age group, the mortality risk was maintained: higher mortality risk in the underweight group (HR=1.50, 95% CI: 1.03 to 2.19 for 1-year mortality; HR=1.42, 95% CI: 1.06 to 1.92 for long-term mortality) and lower mortality risk in the obese group (long-term HR=0.65, 95% CI: 0.52 to 0.83; see [table 4](#T4){ref-type="table"}, Model 2).

![Survival curves in (A) elderly and (B) younger patients with ischaemic stroke according to their body mass index.](bmjopen-2018-028880f02){#F2}

Discussion {#s4}
==========

This study showed that the obesity paradox is not evident in stroke-related mortality. By contrast, the obesity paradox was highly associated with the all-cause death even after accounting for potential confounding of pre-existing comorbidities. We also found that such association exists only in the elderly patients, whereas it vanishes after covariate adjustment in the younger age group.

A study by Dehlendorff *et al* [@R15] reported no obesity paradox for stroke-related short-term mortality, which agrees with the findings of this study. Notably, the study mentioned above only considered death incidence within the first month of post-stroke,[@R15] whereas we considered later deaths caused by recurrent stroke incidences. The effects of obesity on all-cause mortality in patients with ischaemic stroke revealed that higher BMI slightly increases the survival rate across several conditions, given that all-cause mortality denotes the overall survival across all causes of death. Notably, our results are consistent with previous findings on the obesity paradox in patients with stroke. For instance, a study on stroke survivors in Korea revealed a relatively low 1-year all-cause mortality without any evident paradox for 30-day and 90-day all-cause mortalities.[@R17] Findings from this present study also indicate that the underweight group persistently had a higher all-cause mortality risk during short-term, intermediate-term and long-term follow-up periods, and the mortality risk of the overweight group is similar to that of the normal weight group at all points. Furthermore, our study was corroborated by previous findings on increased mortality risk among underweight stroke survivors. Underweight is consistently associated with increased mortality after stroke,[@R3] although the impact of obesity on mortality was reported in a conflicting direction.

After controlling the confounding factors, we observed that the obesity paradox for the all-cause mortality is only found in patients aged 65 years and above. It has been shown that adults aged 65 years and above experience weight loss more frequently than weight gain.[@R44] In addition, weight loss has been shown to be associated with higher mortality risk in older adults[@R44] and even predict mortality independent from chronic disease.[@R46] Another possible explanation for such obesity paradox is a subset of obese people classified as metabolically healthy obese.[@R48] These people seem to be more resistant to the development of obesity-related metabolic diseases. In a study with elderly Koreans aged 60 years and above, the metabolically non-healthy normal weight people were observed to have a remarkably higher risk of all-cause and cardiovascular disease mortality than the overweight or obese people without metabolic syndrome.[@R48]

As far as we know, only a few studies have compared the obesity paradox based on age group[@R4]; even so, the findings were inconsistent. The findings of some of those studies agreed with the results obtained in this study and reported the obesity paradox in patients aged 65 years and above.[@R4] Towfighi *et al* [@R4] reported that obesity is associated with reduced mortality only among elderly survivors.[@R4] A study with women aged 50--79 years also showed that being overweight or obese is associated with low post-stroke mortality.[@R42] Meanwhile, in contrast with our results, some studies reported that the obesity paradox is more prominent in younger patients[@R17] and more prominent in patients with stroke aged less than 65 years. However, it is worth noting that in our study, the obesity paradox in the younger age group became statistically insignificant after adjustment of detailed comorbidities, despite being significant and even more noticeable in the younger age group before the adjustment. This shows that the conflicting results on the obesity paradox in the younger age group might be due to the different methods used in controlling the critical confounding variables in different studies. Considering the relatively small number of participants and deaths in the younger subgroup, larger-scale studies with better control of confounders are needed to enhance further the understanding of the obesity paradox based on age groups. Nevertheless, our findings in this study suggest that, at least in elderly patients with stroke, obesity is not necessarily a risk for mortality.

The obesity paradox in chronic diseases could be explained through biological mechanisms focusing on the advantage of excess fat during illness.[@R49] For instance, weight loss after stroke is a commonly observed phenomenon, which is explained by various mechanisms such as sympathetic activation, fever and inflammation.[@R50] Individuals may lose homeostatic capacity and become more susceptible to the catabolic effect of chronic morbidity or complications. Owing to better metabolic reserves in obese patients, unfavourable metabolic dysregulation might be less common in obese patients.[@R50]

Despite the biological explanation, some studies also raised concerns about inadequate control of confounding variables and reverse causation of the underlying reasons for the observed obesity paradox. Reverse causation occurs when low BMI is not an independent risk factor; instead, it is a consequence of underlying conditions that cause weight loss and then lead to death. However, several studies reported that the mortality risk does not change after excluding patients with life-threatening diseases such as cancer or those who died early in the follow-up period.[@R51] Several studies, including this present study, showed that confounders such as smoking and comorbidities could not entirely explain the obesity paradox.[@R2] A related empirical concern regarding the obesity paradox is a collider-stratification bias that results from conditioning the common effects of exposure and outcome.[@R49] For example, atrial fibrillation, a common risk factor for both ischaemic stroke and mortality,[@R1] is a higher risk for mortality than obesity among patients with stroke; thus, one could falsely observe the protective effect of obesity on mortality when not adjusting for atrial fibrillation in obesity regression on stroke-related mortality. This highlights the importance of comprehensive control of comorbidities and stroke severity in estimating the obesity paradox in patients with stroke as in the current study. We acknowledge that there are conflicting findings in previous studies regarding the collider bias and obesity paradox after controlling for it.[@R15] This study adjusted for stroke severity and various comorbidities using CCI to estimate the net effect of obesity on mortality in patients with stroke considering the effect that may result because of the uncertainty of the kind of relationship that exists between various comorbidities with obesity and mortality.

Notwithstanding, this study has several limitations. First, this is a hospital-based study involving a single tertiary hospital whose data could not be generalised. However, this could also be an advantage of the study. Since patients received relatively uniform treatments at the same hospital, a potential confounder from different treatments could be minimised. Moreover, we retrieved the data from a registry in which the clinical information had been maintained in a standard pre-defined way. Second, we evaluated the body composition as BMI, which cannot differentiate between elevated body fat content and preserved or increased lean mass.[@R54] Measurement of fat distribution such as waist-to-hip ratio or waist circumference could probably be more suitable in assessing the effect of obesity on stroke-related mortality. Third, in the analysis, we excluded patients without BMI information. The missing weight or height data could be due to the patient's extremely severe status or inability to stand up. These patients without recorded body weight and height information apparently had a higher NIHSS score and higher mortality rate in the unadjusted analysis. Therefore, in this study, it is possible that the obesity paradox was underestimated by excluding the patients with missing BMI data.

Despite the shortcomings, this study made several significant contributions. First, we evaluated the relationship between BMI and mortality risk by controlling the variables related to various diseases, which could not be obtained in previous studies, including some potential confounders such as active cancer, depression, dementia, anaemia, other medical severity at admission and complications during stroke treatment. Second, as mentioned earlier, we addressed the existence of multi-morbidity by CCI. To the best of our knowledge, CCI has not been considered a confounding variable in any study in analysing the effect of the obesity paradox on mortality in stroke survivors.[@R2] Third, the covariates measurements were rigorously performed. Previous studies included initial blood pressure or glucose level as a surrogate marker of cardiovascular disease severity. However, they did not mention the risk associated with the assessment method but only considered the increment in those levels as a severity indicator.[@R2]
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